1. Short title This Act may be cited as the National Commission on Scleroderma and Fibrotic Diseases Act of 2018 . 2. National Commission on Fibrotic Diseases (a) Establishment There is established, within the National Institutes of Health, a National Commission on Fibrotic Diseases (referred to in this section as the Commission ) to evaluate and make recommendations regarding improvements to the coordination and advancement of research activities related to fibrosis and fibrotic diseases, which may include scleroderma as a prototypical condition that can cause fibrosis in various organs, supported by the National Institutes of Health. (b) Membership (1) In general The Commission shall be composed of the following voting members: (A) The Director of NIH, or the designee of such director. (B) The Directors of the following Institutes, or their designees: (i) The National Institute of Arthritis and Musculoskeletal and Skin Diseases. (ii) The National Heart, Lung, and Blood Institute. (iii) The National Institute of Diabetes and Digestive and Kidney Diseases. (iv) The National Human Genome Research Institute. (v) Any other national research institute or center with an active fibrotic disease research portfolio. (C) Twelve additional voting members appointed under paragraph (2). (2) Additional members The Commission shall include voting members, appointed by the Director of NIH, with expertise in the prevention, care, and epidemiology of any of the diseases and complications described in subsection (a), including one or more such members from each of the following categories: (A) Leading scientists or physicians with research expertise in the conditions described in subsection (a). (B) Patient advocates with a perspective on the conditions described in subsection (a). (3) Chairperson The members of the Commission shall select a chairperson from the members appointed under paragraph (2). (4) Meetings The Commission shall meet 3 times per year. (5) Vacancies A vacancy on the Commission shall be filled in the same